Cigna Investments Inc. New bought a new stake in shares of Encompass Health Corp (AMEX:EHC) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 3,665 shares of the company’s stock, valued at approximately $210,000.
A number of other large investors have also recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Encompass Health during the 1st quarter valued at $622,184,000. Victory Capital Management Inc. acquired a new stake in Encompass Health during the 1st quarter valued at $101,978,000. Northern Trust Corp acquired a new stake in Encompass Health during the 1st quarter valued at $88,764,000. Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in Encompass Health during the 4th quarter valued at $65,366,000. Finally, Eagle Asset Management Inc. acquired a new stake in Encompass Health during the 4th quarter valued at $53,001,000. 93.18% of the stock is currently owned by institutional investors.
AMEX EHC opened at $57.67 on Thursday. Encompass Health Corp has a 1-year low of $40.86 and a 1-year high of $59.29. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 1.89.
The firm also recently announced a quarterly dividend, which will be paid on Monday, July 16th. Shareholders of record on Monday, July 2nd will be given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 1.73%. The ex-dividend date of this dividend is Friday, June 29th.
Several analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Encompass Health from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. Credit Suisse Group upped their price target on shares of Encompass Health from $61.00 to $65.00 and gave the stock an “outperform” rating in a research note on Friday, March 16th. Robert W. Baird reaffirmed an “outperform” rating and issued a $66.00 price target (up from $59.00) on shares of Encompass Health in a research note on Monday, April 30th. Craig Hallum reaffirmed a “buy” rating and issued a $71.00 price target (up from $63.00) on shares of Encompass Health in a research note on Monday, April 30th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $70.00 price target on shares of Encompass Health in a research note on Tuesday, April 17th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company. Encompass Health has a consensus rating of “Buy” and a consensus price target of $64.10.
In other Encompass Health news, CEO Mark J. Tarr sold 33,100 shares of the stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $60.96, for a total transaction of $2,017,776.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Cheryl B. Levy sold 30,982 shares of the stock in a transaction on Wednesday, May 9th. The stock was sold at an average price of $63.00, for a total transaction of $1,951,866.00. The disclosure for this sale can be found here. Insiders have sold 69,777 shares of company stock worth $4,326,032 over the last three months. Company insiders own 1.60% of the company’s stock.
Encompass Health Profile
Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 35 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.